NCT06140485 is a Phase 3 clinical trial of NW Low-Glu® in Diabetes Mellitus, Type 2, sponsored by Natural Wellness Egypt.

Who is sponsoring NCT06140485?

NCT06140485 is sponsored by Natural Wellness Egypt.

What drugs are being tested in NCT06140485?

Interventions in NCT06140485: NW Low-Glu®, Metformin.

What condition does NCT06140485 study?

NCT06140485 studies Diabetes Mellitus, Type 2.

Is NCT06140485 still recruiting?

NCT06140485 is currently status unknown. Last updated 20 November 2023.

Last reviewed 2023-11-20 · How we verify

NCT06140485

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III, Randomized, Double-Blind, Double-Dummy, Active- Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients With Type II Diabetes Mellitus

Status unknown Phase 3 Last updated 20 November 2023

What this trial tests

Phase 3 trial testing NW Low-Glu® in Diabetes Mellitus, Type 2 in 400 participants. Status unknown.

Timeline

1 March 2024

Primary endpoint
1 September 2025

1 October 2025

Quick facts

Lead sponsor	Natural Wellness Egypt
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	400
Start date	1 March 2024
Primary completion	1 September 2025
Estimated completion	1 October 2025

Drugs / interventions tested

NW Low-Glu®
Metformin (metformin) — full drug profile →

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Natural Wellness Egypt — full company profile →

Who can join

Adults 18 to 65, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Comparing the mean change in HbA1c levels between the experimental arm and the active-control arm
Time frame: 6 months
To compare the hypoglycemic effect of a herbal medicinal product (NW Low-Glu) to that of metformin as measured by the mean change in HbA1c levels in patients with type II diabetes mellitus.

Sponsor's own description

The goal of this clinical trial is to investigate efficacy and safety of an herbal medicinal product of (NW Low-Glu®) in patients with Type 2 Diabetes Mellitus (T2DM). The main question\[s\] it aims to answer are: • What will be the mean change in HbA1c levels in the experimental arm (NW Low-Glu®) compared to the active-control arm (metformin) after 6 months of treatment? Participants will randomized in a 1:1 allocation ratio, into one of the two treatment groups, to receive either Metformin or NW Low-Glu®. Researchers will compare the mean change in HbA1C, fasting blood glucose, and weight between the experimental arm and the active-control arm.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

<i>Nigella sativa</i>: A Comprehensive Review of Its Therapeutic Potential, Pharmacological Properties, and Clinical Applications.
Alberts A, Moldoveanu ET, Niculescu AG, Grumezescu AM. · · 2024 · cited 12× · PMID 39769174 · DOI 10.3390/ijms252413410

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Natural Wellness Egypt trials

Trials by the same sponsor.

NCT05347329 — A Clinical Trial to Investigate the Efficacy and Safety of Tongkat Ali Maca Plus · NA · completed
NCT05343780 — Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of NASH · Phase 2 · completed
NCT05343767 — Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06140485 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Natural Wellness Egypt
Last refreshed: 20 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06140485.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing